Eisai Gains Most in 18 Months on Approval of Stronger Aricept
This article is for subscribers only.
Eisai Co. gained the most in 18 months in Tokyo trading after winning U.S. regulatory approval to sell a higher-dose version of Aricept, the world’s bestselling treatment for Alzheimer’s disease.
Eisai jumped as much as 5.1 percent to 2,920 yen in intraday trade, its steepest gain since Jan. 22, 2009. The stock was at 2,901 yen at 10:31 a.m. local time, paring its loss this year to 15 percent, compared with a 9.5 percent decline on the benchmark Nikkei 225 Stock Average.